Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Hypersensitivity and allergy

Supply of adrenaline auto-injectors returns to normal

The interim protocol for the dispensing of adrenaline 150 microgram auto-injectors will cease to be in effect from 29 November 2018, the NHS has said.

Sufficient stock levels are now available of all three brands of junior and adult adrenaline auto-injectors, Jext, EpiPen and Emerade.

However, wholesaler prescription validation will remain in place for EpiPen only until further notice.

The shortage of EpiPens was first highlighted in May 2018 when the UK supplier Mylan identified shortcomings owing to manufacturing problems. Supplies of Jext and Emerade 0.15mg adrenaline auto-injectors were then rapidly depleted as a knock-on effect of the supply problems.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205820

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.